MindWalk Holdings Corp (NASDAQ:HYFT), a Bio-Native AI company pioneering the integration of artificial intelligence, multi-omics data, and advanced laboratory research, stock fell 10.23% (As on September 16, 11:24:29 AM UTC-4, Source: Google Finance) after the company posted lower than expected results for the first quarter of FY 26. The divestiture of the Netherlands operations generated $16.1 million in proceeds, further strengthening the balance sheet. The company is advancing the transformation into a fully integrated BioIntelligence company. It has introduced MindWalk, uniting ImmunoPrecise Antibodies, BioStrand, and Talem under one cohesive identity. During the quarter, the company has also advanced the dengue vaccine into preclinical manufacturing and further validated the LensAI platform to de-risk biologics development for partners. The next step with that, one certainly being that the company is actually working really close with the NIH, the arm of the NIH that deals with infectious disease and allergies. The company has progressed into preclinical manufacturing and in vivo studies, demonstrating LensAI’s translational potential across infectious diseases. The company has expanded validation of LensAI, showing predictive ability for Anti-Drug-Antibody risk, helping partners accelerate programs and reduce costly late-stage failures. Cash & Equivalents: $5.0 million at July 31, 2025, excluding $16.1 million in net proceeds from the Netherlands divestiture received in early Q2. The company has also introduced the new ticker, HIFT, or H-Y-F-T, highlighting the foundational role of our HIFT technology in redefining biologics discovery.

HYFT in the first quarter of FY 26 has reported the adjusted loss per share of $0.07, missing the analysts’ estimates for the adjusted loss per share of $0.04, according to the Zacks Consensus Estimate. The company had reported the adjusted revenue growth of 45 percent to $2.29 million in the first quarter of FY 26, missing the analysts’ estimates for revenue by 44.67%. Gross Profit was $4.0 million (53% margin), up from $2.4 million (45% margin). Continued ops contributed $1.5 million at 48% margin; discontinued ops contributed $2.5 million at 56% margin. Operating Loss was $2.7 million total, versus $4.7 million last year. Includes $4.1 million loss from continuing ops and $1.1 million income from discontinued ops. Net Loss was $3.0 million total, versus $4.0 million last year. Includes $4.1 million loss from continuing ops and $1.1 million income from discontinued ops. Adjusted EBITDA was Loss of $1.4 million, versus $2.8 million last year. Includes $2.1 million loss from continuing ops and $0.7 million income from discontinued ops.